Source: http://www.firstwordpharma.com/
TOKYO, JAPAN – March 28, 2016 – PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TSE First Section:4587) announced today that it has entered into a multi-target discovery and development collaboration with Tokyo-based Asahi Kasei Pharma Corp.(“Asahi Kasei Pharma”), a division of Asahi Kasei Corp. (TSE First Section: 3407). PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocylic/constrained peptides against multiple targets of interest selected by Asahi Kasei Pharma, and to optimize hit peptides into therapeutic peptides. Asahi Kasei Pharma will have the right to develop and commercialize all molecules resulting from the collaboration. Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, research funding and is eligible for payments associated with the achievement of certain preclinical and clinical development milestones. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.
Read more: http://www.firstwordpharma.com/node/1370310?tsid=28®ion_id=4#axzz44RvqhWDx